Cardiorenal injury and nitric oxide synthase activity in hypertension

Leopoldo Raij, H. Hayakawa, E. Jaimes

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Nitric oxide (NO) is an endogenous vasodilator and antithrombogenic agent synthesized in the endothelium by a constitutive NO synthase (NOS). In addition, NO is a powerful endogenous inhibitor of growth-related responses in vascular cells and thereby participates in vascular remodeling in response to injury. In the kidney, NO inhibits mesangial cell hypertrophy and hyperplasia as well as mesangial cell synthesis of extracellular matrix. In the heart and systemic vessels, NO modulates vascular smooth muscle cell hypertrophy as well as hyperplasia. In endothelial cells, shear stress and cyclic strain, physical forces known to be operative during hypertensive states, induce a parallel increase in endothelial NOS expression, NOS protein, and NOS activity. Recent studies in animals suggest that in hypertension the physiological adaptation to the increased hemodynamic workload is the upregulation of vascular NOS activity. Moreover, upregulation of NOS activity may contribute to forestalling end-organ complications of hypertension, namely renal failure, left ventricular hypertrophy, coronary artery disease, and stroke. Conversely, failiure to augment, or an actual decrease in vascular NOS activity, increases the susceptibility of end-organs to hypertensive injury. Studies in genetic models of hypertension in rats support this contention and suggest that vascular NOS activity in response to hypertension may be genetically determined and varies in different strains of rats. On the basis of these studies in animals and preliminary studies in humans we speculate that genetically conditioned heterogeneity in vascular NOS activity in response to hypertension may explain, at least in part, the differences in end-organ disease observed clinically in individuals with hypertension of similar severity.

Original languageEnglish
JournalJournal of Hypertension, Supplement
Volume16
Issue number8
StatePublished - Dec 1 1998
Externally publishedYes

Fingerprint

Nitric Oxide Synthase
Hypertension
Wounds and Injuries
Blood Vessels
Nitric Oxide
Mesangial Cells
Hypertrophy
Hyperplasia
Up-Regulation
Physiological Adaptation
Growth Inhibitors
Genetic Models
Left Ventricular Hypertrophy
Workload
Vasodilator Agents
Vascular Smooth Muscle
Smooth Muscle Myocytes
Endothelium
Renal Insufficiency
Extracellular Matrix

Keywords

  • Angiotensin II
  • Endothelin-1
  • Glomerulus
  • Hypertension
  • Nitric oxide
  • Vasoconstriction

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Cardiorenal injury and nitric oxide synthase activity in hypertension. / Raij, Leopoldo; Hayakawa, H.; Jaimes, E.

In: Journal of Hypertension, Supplement, Vol. 16, No. 8, 01.12.1998.

Research output: Contribution to journalArticle

Raij, Leopoldo ; Hayakawa, H. ; Jaimes, E. / Cardiorenal injury and nitric oxide synthase activity in hypertension. In: Journal of Hypertension, Supplement. 1998 ; Vol. 16, No. 8.
@article{c69f3914ad2d426db346cff67650a953,
title = "Cardiorenal injury and nitric oxide synthase activity in hypertension",
abstract = "Nitric oxide (NO) is an endogenous vasodilator and antithrombogenic agent synthesized in the endothelium by a constitutive NO synthase (NOS). In addition, NO is a powerful endogenous inhibitor of growth-related responses in vascular cells and thereby participates in vascular remodeling in response to injury. In the kidney, NO inhibits mesangial cell hypertrophy and hyperplasia as well as mesangial cell synthesis of extracellular matrix. In the heart and systemic vessels, NO modulates vascular smooth muscle cell hypertrophy as well as hyperplasia. In endothelial cells, shear stress and cyclic strain, physical forces known to be operative during hypertensive states, induce a parallel increase in endothelial NOS expression, NOS protein, and NOS activity. Recent studies in animals suggest that in hypertension the physiological adaptation to the increased hemodynamic workload is the upregulation of vascular NOS activity. Moreover, upregulation of NOS activity may contribute to forestalling end-organ complications of hypertension, namely renal failure, left ventricular hypertrophy, coronary artery disease, and stroke. Conversely, failiure to augment, or an actual decrease in vascular NOS activity, increases the susceptibility of end-organs to hypertensive injury. Studies in genetic models of hypertension in rats support this contention and suggest that vascular NOS activity in response to hypertension may be genetically determined and varies in different strains of rats. On the basis of these studies in animals and preliminary studies in humans we speculate that genetically conditioned heterogeneity in vascular NOS activity in response to hypertension may explain, at least in part, the differences in end-organ disease observed clinically in individuals with hypertension of similar severity.",
keywords = "Angiotensin II, Endothelin-1, Glomerulus, Hypertension, Nitric oxide, Vasoconstriction",
author = "Leopoldo Raij and H. Hayakawa and E. Jaimes",
year = "1998",
month = "12",
day = "1",
language = "English",
volume = "16",
journal = "Journal of Hypertension, Supplement",
issn = "0952-1178",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Cardiorenal injury and nitric oxide synthase activity in hypertension

AU - Raij, Leopoldo

AU - Hayakawa, H.

AU - Jaimes, E.

PY - 1998/12/1

Y1 - 1998/12/1

N2 - Nitric oxide (NO) is an endogenous vasodilator and antithrombogenic agent synthesized in the endothelium by a constitutive NO synthase (NOS). In addition, NO is a powerful endogenous inhibitor of growth-related responses in vascular cells and thereby participates in vascular remodeling in response to injury. In the kidney, NO inhibits mesangial cell hypertrophy and hyperplasia as well as mesangial cell synthesis of extracellular matrix. In the heart and systemic vessels, NO modulates vascular smooth muscle cell hypertrophy as well as hyperplasia. In endothelial cells, shear stress and cyclic strain, physical forces known to be operative during hypertensive states, induce a parallel increase in endothelial NOS expression, NOS protein, and NOS activity. Recent studies in animals suggest that in hypertension the physiological adaptation to the increased hemodynamic workload is the upregulation of vascular NOS activity. Moreover, upregulation of NOS activity may contribute to forestalling end-organ complications of hypertension, namely renal failure, left ventricular hypertrophy, coronary artery disease, and stroke. Conversely, failiure to augment, or an actual decrease in vascular NOS activity, increases the susceptibility of end-organs to hypertensive injury. Studies in genetic models of hypertension in rats support this contention and suggest that vascular NOS activity in response to hypertension may be genetically determined and varies in different strains of rats. On the basis of these studies in animals and preliminary studies in humans we speculate that genetically conditioned heterogeneity in vascular NOS activity in response to hypertension may explain, at least in part, the differences in end-organ disease observed clinically in individuals with hypertension of similar severity.

AB - Nitric oxide (NO) is an endogenous vasodilator and antithrombogenic agent synthesized in the endothelium by a constitutive NO synthase (NOS). In addition, NO is a powerful endogenous inhibitor of growth-related responses in vascular cells and thereby participates in vascular remodeling in response to injury. In the kidney, NO inhibits mesangial cell hypertrophy and hyperplasia as well as mesangial cell synthesis of extracellular matrix. In the heart and systemic vessels, NO modulates vascular smooth muscle cell hypertrophy as well as hyperplasia. In endothelial cells, shear stress and cyclic strain, physical forces known to be operative during hypertensive states, induce a parallel increase in endothelial NOS expression, NOS protein, and NOS activity. Recent studies in animals suggest that in hypertension the physiological adaptation to the increased hemodynamic workload is the upregulation of vascular NOS activity. Moreover, upregulation of NOS activity may contribute to forestalling end-organ complications of hypertension, namely renal failure, left ventricular hypertrophy, coronary artery disease, and stroke. Conversely, failiure to augment, or an actual decrease in vascular NOS activity, increases the susceptibility of end-organs to hypertensive injury. Studies in genetic models of hypertension in rats support this contention and suggest that vascular NOS activity in response to hypertension may be genetically determined and varies in different strains of rats. On the basis of these studies in animals and preliminary studies in humans we speculate that genetically conditioned heterogeneity in vascular NOS activity in response to hypertension may explain, at least in part, the differences in end-organ disease observed clinically in individuals with hypertension of similar severity.

KW - Angiotensin II

KW - Endothelin-1

KW - Glomerulus

KW - Hypertension

KW - Nitric oxide

KW - Vasoconstriction

UR - http://www.scopus.com/inward/record.url?scp=0032467296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032467296&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0032467296

VL - 16

JO - Journal of Hypertension, Supplement

JF - Journal of Hypertension, Supplement

SN - 0952-1178

IS - 8

ER -